ABSTRACT

Introduction Abnormal Uterine bleeding (AUB) can seriously affect the quality of life of women since it interferes with the physical, emotional, social, and material quality of life and may identify serious health concerns as the adolescent transitions to adulthood. Methods A prospective cohort study was performed in 250 individuals diagnosed with AUB are screened for inclusion and exclusion criteria. The safety and efficacy were evaluated by using PBAC score, hemoglobin levels, and MMAS score. The improvement of lab parameters is assessed by performing data analysis by using paired t test and significance p-value. Results: The change in PBAC score was from 226.16±18.63 to 80.19±10.88 in group-1 and in group-2 it was from 223.80±18.56 to 83.34±10.21, the significant reduction in PBAC scores is seen more in the tranexamic acid+mefenamic acid group. The improvement in the quality of life, MMAS score was from 41.67±12.84± to 84.75±11.99 in group-1 and in group -2 it was from 41.13±13.73 to 81.08±14.15, improvement in the QoL is seen more in tranexamic acid+mefenamic acid group. The reduction of pain is seen in tranexamic acid+mefenamic acid treated group is 80% which is higher than the tranexamic acid alone treated group i.e. 38.09% after 3 months. Conclusion: Our studyconcludes that tranexamic acid+mefenamic acid combination is superior and safer in reducing menstrual blood loss and is also safe in reducing the pain, menstrual cramps during uterine bleeding and improvement in the patients wellbeing, enhancing quality of life. Keywords: Abnormal uterine bleeding (AUB), Tranexamic acid (TXA), Mefenamic acid, Pictorial Blood loss Assessment Chart (PBAC), Menorrhagia Multi-attribute Scale (MMAS), Quality of Life (QoL)
Publication date: 01/04/2025

https://ijbpas.com/pdf/2025/April/MS_IJBPAS_2025_8921.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.4.8921